Meeting highlights from ICMRA global regulatory workshop on COVID-19 observational studies and real world data

EMA

16 April 2020 - Observational studies of data generated in clinical practice in the context of COVID-19 can contribute to the development, authorisation and monitoring of the safety and efficacy of medicines and vaccines to prevent and treat COVID-19.

Closer collaboration between international medicines regulators and information sharing in this area will benefit patients around the world. 

This is highlighted in the summary of the latest global regulatory workshop on COVID-19 observational studies and real world data, organised under the umbrella of the International Coalition of Medicines Regulatory Authorities (ICMRA), which has been published today.

Read EMA press release

Michael Wonder

Posted by:

Michael Wonder